NOMAD Power Solutions, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $78.6M
- Price
- $4.30
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.14%
- Volume
- 166.1K
About
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.
Quick stats
Shares outstanding18.3M
Computed float12.8M
Float / shares69.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001335105
Websitehttps://nomadpower.com
AI Summary
AI-generated1/9
minorbullishother
The Grid Queue Runs Five Years. This Equipment Ships on a Truck.
This sponsored commentary references Equinix to illustrate the power demand constraints facing data center operators, summarizing previously reported Q2 2026 financial results.
The article highlights $2.6 billion in revenue, a 53% Adjusted EBITDA margin, and record annualized gross bookings of $424 million, driven by double-digit growth in monthly recurring revenue.
Equinix management plans $5 billion to $7 billion in annual capital expenditure through 2029 to expand capacity amid multi-year grid interconnection delays.
Red flags
- Paid advertisement/sponsored content for NOMAD Power Solutions
- Summarizes previously disclosed Q2 2026 earnings; no new material information regarding Equinix